London, UK – October 8, 2026 – Despite significant strides in addressing women’s health inequities, a critical data gap and insufficient investor confidence continue to hinder the full realization of innovative healthcare solutions for women globally. This was the prevailing sentiment at the Women’s Health Week Europe conference, held in London from October 7-8, 2026. While a more optimistic outlook emerged compared to previous years, marked by a notable increase in investment and policy focus, industry leaders, researchers, and investors underscored the urgent need for inclusionary research practices and enhanced investor education to unlock the full potential of women’s health advancements.
The stark reality of underfunding in women’s health research and development (R&D) has long been a critical concern. Between 2020 and 2025, companies dedicated solely to women’s health attracted less than 1% of private healthcare investment, according to the World Economic Forum (WEF). This disparity not only impacts the development of new treatments and technologies but also perpetuates a cycle of inadequate understanding of diseases and conditions that disproportionately affect or exclusively impact women. However, the recent conference painted a more hopeful picture, showcasing burgeoning innovation and a growing recognition of the significant economic and societal returns on investment in this vital sector.
The Urgency of Inclusion: Addressing the Data Gap in Women’s Health
A recurring theme throughout the conference was the pervasive data gap that complicates the development of new drugs and health technologies. This gap stems from a historical exclusion of women in clinical trials and a lack of sex-disaggregated data analysis in research.
"For too long, the medical community has operated under the assumption that ‘one size fits all’ when it comes to health," stated Dr. Lale Say, Unit Head at the World Health Organization (WHO). "This approach has had serious consequences, leading to a diminished understanding of drug safety and efficacy in women, and consequently, higher rates of adverse events. We must move beyond this outdated paradigm."
The statistics underscore the severity of this issue. Currently, 72% of clinical trials do not aggregate outcomes based on sex, meaning critical differences in how treatments affect men and women are often missed. This oversight can lead to a higher incidence of drug-related serious treatment-emergent adverse events (TEAEs) in women. To combat this, Dr. Say emphasized the imperative for sponsors to routinely include sex disaggregation in their analyses. "Baking this into global policy can help researchers identify potential differences in safety risks among the sexes, whether those risks are skewed towards men or women," she explained.
Beyond sex, experts also highlighted the need for a more nuanced understanding of diversity within the female population. "Women are not a homogeneous group; there’s intersectionality at play," commented Maryann Ferreux, CMO at Health Innovation Kent Surrey Sussex. She stressed that factors beyond sex, such as social demographics, must be considered when striving to close the data gap. This means actively recruiting women from diverse ethnic backgrounds, socioeconomic statuses, and geographical locations to ensure research findings are representative of the real world.
Furthermore, Alison Cave, Chief Safety Officer of the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), called for increased data collection regarding drug safety and efficacy in pregnant and lactating individuals. Information remains scarce on how essential medications might impact both mothers and their children, a critical area that requires immediate attention. Collecting more data, both pre- and post-marketing, is crucial for a comprehensive understanding of a treatment’s true impact.
The Funding Landscape: Navigating Investment for Women’s Health Innovation
Securing adequate funding remains a significant hurdle for startups and innovators in the women’s health sector. Henriette Hessen, Investment Director at Verdane, pointed to a broader systemic issue: a general lack of women in decision-making roles within the finance industry, which can inadvertently create biases in investment strategies.
While venture capital (VC) has historically been a primary source of early-stage funding, speakers at the conference advocated for a more diversified approach. Michael Lewis, Scientific Director of Innovation for the UK’s National Institute for Health and Care Research (NIHR), highlighted the potential of grant and debt funding, both as standalone options and in blended financing models. These avenues can offer greater flexibility for companies as they scale.
The geographical disparity in funding has also been a notable challenge, with capital traditionally concentrating in the US over Europe. However, this trend is shifting. Jemma Day, Investment Manager at the British Business Bank, reported a record flow of funding into women’s health in the UK and Europe in 2025, signaling a positive change.
Despite this progress, nuances exist in the investor landscape. Hessen noted that later-stage investors in the US are more commonly specialists in specific areas of women’s health, while their European counterparts tend to be more generalist. This difference can impact the type of support and expertise available to growing companies.
Ravit Warsha Dor, Partner and Director at Telus Global Ventures, also cautioned companies to prepare for disruption driven by the surge of artificial intelligence (AI)-native companies. She observed that these newer, AI-focused ventures are often outperforming more established companies still grappling with legacy technologies, a trend that will undoubtedly shape the investment landscape moving forward.
Optimizing Research and Development for Better Outcomes
The path to improving women’s health extends beyond funding and data collection; it necessitates a fundamental re-evaluation of how R&D is conducted. The historical testing of many widely prescribed drugs primarily on male subjects has created a knowledge deficit regarding their safety and efficacy in women.
"This isn’t just an academic problem; it has real-world consequences for patient safety," warned Dr. Cave. She stressed the importance of building a more inclusive approach into the very fabric of clinical trial design. This includes ensuring that women, particularly those from marginalized groups, are adequately represented. The challenge lies in recognizing and addressing the intersectionality of factors that influence health outcomes.
The conference also explored innovative approaches to clinical trial optimization. Discussions centered on leveraging technology, such as real-world data and decentralized clinical trials, to improve recruitment, reduce participant burden, and accelerate the development timeline. The goal is to create a more efficient and effective pathway from discovery to patient access.
Systemic Challenges and the Road to Health Equity
Achieving true health equity for women requires dismantling deeply ingrained systemic challenges. The conference identified several key areas:
- Combating Misogyny: Addressing pervasive misogyny within both the healthcare system and broader society is paramount. This requires a cultural shift that values women’s health concerns and prioritizes their well-being.
- Bolstering Funding Flow: Continued advocacy and strategic investment are crucial to ensure sustained financial support for women’s health initiatives. This involves not only public funding but also attracting private investment and philanthropic contributions.
- Implementing Gender-Responsive Policies: Policymakers have a critical role to play in enacting legislation and regulations that support women’s health research, access to care, and equitable outcomes. This includes mandates for sex-disaggregated data and the inclusion of women in clinical trials.
The consensus among speakers was that this transformation cannot be a solo endeavor. It requires a concerted, global effort involving investors, clinicians, regulators, policymakers, and founders. The disproportionate impact of health disparities on women from disadvantaged backgrounds underscores the urgency of this global collaboration.
"We are seeing incredible innovation emerge, but the ultimate measure of success will be widespread access," stated the CEO of the period tracker app, Clue. She emphasized that for any therapeutic or health technology to be truly beneficial, its distribution and accessibility must be a fundamental focus from the earliest stages of development.
The Promise of a Healthier Future
While acknowledging the significant hurdles that remain, the Women’s Health Week Europe conference concluded on a note of cautious optimism. The increased dialogue, growing investment, and a clearer understanding of the challenges suggest a potential tipping point for women’s health innovation. By prioritizing inclusionary research, educating investors on the substantial economic and societal returns, and addressing systemic barriers, the sector is charting a course toward a future where women can expect equitable, effective, and accessible healthcare solutions. The journey is far from over, but the commitment to bridging the data gap and unlocking the full promise of women’s health advancements is stronger than ever.
About the Author
